GSE111247 temozolomide LN-308 2 v 12 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE111247_temozolomide_LN-308_2_v_12_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE111247_temozolomide_LN-308_2_v_12_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE111247_temozolomide_LN-308_2_v_12_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE111247_temozolomide_LN-308_2_v_12_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

keratin 8 pseudogene 36

Gene

TMEM123 divergent transcript

Gene

ribosomal protein L13a pseudogene 5

Gene

uncharacterized LOC105377411

Gene

uncharacterized LOC105377543

Gene

IGF2BP2 antisense RNA 1

Gene

GJD4 antisense RNA 1

Gene

5-hydroxytryptamine receptor 5B, pseudogene

Gene

ribosomal protein L17 pseudogene 38

Gene

karyopherin subunit alpha 2 pseudogene 1

  • Gene

    keratin 8 pseudogene 36


  • Gene

    TMEM123 divergent transcript


  • Gene

    ribosomal protein L13a pseudogene 5


  • Gene

    uncharacterized LOC105377411


  • Gene

    uncharacterized LOC105377543


  • Gene

    IGF2BP2 antisense RNA 1


  • Gene

    GJD4 antisense RNA 1


  • Gene

    5-hydroxytryptamine receptor 5B, pseudogene


  • Gene

    ribosomal protein L17 pseudogene 38


  • Gene

    karyopherin subunit alpha 2 pseudogene 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.